Vertex Announces U.S. FDA Approval for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
BOSTON--(BUSINESS WIRE)--Vertex today announced the U.S. FDA has approved TRIKAFTA for certain children with cystic fibrosis ages 6-11 years old. ...
